Burlando Martina, Algeri Adelaide, Salvi Ilaria, Cozzani Emanuele, Parodi Aurora
All authors are with the Section of Dermatology, DISSAL, at the University of Genoa, Ospedale-Policlinico San Martino, IRCCS in Genova, Italy and IRCCS Ospedale Policlinico San Martino in Genova, Italy.
J Clin Aesthet Dermatol. 2024 Nov;17(11):45-49.
Dimethyl fumarate (DMF) is an oral treatment approved by the European Medicines Agency (EMA) to treat moderate-to-severe plaque psoriasis among adult patients.
This study aims to evaluate sociodemographic, anthropometric, and medical characteristics in patients with psoriasis without previous history of traditional systemic therapy and to observe if the efficacy or AEs of dimethyl fumarate correlate to any of the patients' characteristics.
Ninety-two patients with mild-to-moderate psoriasis were enrolled. Each patient was reviewed at 4, 12, 24 and 36 weeks. The PASI score and any clinical side effects or blood count abnormalities were recorded.
After 4 weeks, a decrease in the median value of PASI index was already noticeable (p<0.001). After 12 weeks of treatment, 43.9% of patients reached PASI-50, 12.3% PASI-75. The patients achieving PASI-75 after 12 weeks of treatment were significantly younger than those who did not. Age, BMI index, gender and gastroprotection used were not significantly related to the occurrence of side effects.
Profiling of patients could be useful in predicting the response to treatment. In our study, younger patients were found to respond better to dimethyl fumarate.
富马酸二甲酯（DMF）是一种经欧洲药品管理局（EMA）批准用于治疗成年中重度斑块状银屑病的口服药物。
本研究旨在评估既往无传统系统治疗史的银屑病患者的社会人口学、人体测量学和医学特征，并观察富马酸二甲酯的疗效或不良事件是否与患者的任何特征相关。
纳入92例轻至中度银屑病患者。每位患者在第4、12、24和36周接受复查。记录银屑病面积和严重程度指数（PASI）评分以及任何临床副作用或血细胞计数异常情况。
4周后，PASI指数中位数的下降已经很明显（p<0.001）。治疗12周后，43.9%的患者达到PASI-50, 12.3%的患者达到PASI-75。治疗12周后达到PASI-75的患者明显比未达到的患者年轻。年龄、体重指数、性别和使用的胃保护措施与副作用的发生无显著相关性。
对患者进行特征分析有助于预测治疗反应。在我们的研究中，发现年轻患者对富马酸二甲酯的反应更好。
